[go: up one dir, main page]

WO2006087550A8 - Amyloid-binding peptides, analogues and uses thereof - Google Patents

Amyloid-binding peptides, analogues and uses thereof

Info

Publication number
WO2006087550A8
WO2006087550A8 PCT/GB2006/000539 GB2006000539W WO2006087550A8 WO 2006087550 A8 WO2006087550 A8 WO 2006087550A8 GB 2006000539 W GB2006000539 W GB 2006000539W WO 2006087550 A8 WO2006087550 A8 WO 2006087550A8
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
analogues
peptide
compositions
chemical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/000539
Other languages
French (fr)
Other versions
WO2006087550A3 (en
WO2006087550A2 (en
Inventor
Andrew Doig
Kelvin Stott
Jody Mason
Nicoleta Kokkoni
Hozefa Amijee
Mark Treherne
David Scopes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senexis Ltd
Original Assignee
Senexis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Ltd filed Critical Senexis Ltd
Priority to EP06709776A priority Critical patent/EP1853626A2/en
Priority to AU2006215406A priority patent/AU2006215406A1/en
Priority to JP2007555695A priority patent/JP2008530194A/en
Priority to CA002598080A priority patent/CA2598080A1/en
Publication of WO2006087550A2 publication Critical patent/WO2006087550A2/en
Publication of WO2006087550A8 publication Critical patent/WO2006087550A8/en
Publication of WO2006087550A3 publication Critical patent/WO2006087550A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

The present invention relates to chemical compounds and compositions comprising amyloid-binding peptide sequences, or analogues and derivatives thereof, which bind to a target amyloid-forming protein or peptide. The amyloid-binding peptide sequences are not essentially derived from or otherwise based on any section of the target amyloid-forming protein or peptide, and they comprise a minimum number of non-natural amino acid side chains. The chemical compounds and compositions are useful for the diagnosis and treatment of diseases and disorders associated with a fundamental pathogenic process of protein or peptide misfolding and aggregation, called 'amyloidosis'.
PCT/GB2006/000539 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof Ceased WO2006087550A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06709776A EP1853626A2 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
AU2006215406A AU2006215406A1 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
JP2007555695A JP2008530194A (en) 2005-02-18 2006-02-16 Amyloid binding peptides, analogs and uses thereof
CA002598080A CA2598080A1 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0503434.3A GB0503434D0 (en) 2005-02-18 2005-02-18 Amyloid-binding peptides, analogues and uses thereof
GB0503434.3 2005-02-18

Publications (3)

Publication Number Publication Date
WO2006087550A2 WO2006087550A2 (en) 2006-08-24
WO2006087550A8 true WO2006087550A8 (en) 2006-12-14
WO2006087550A3 WO2006087550A3 (en) 2007-05-24

Family

ID=34400981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000539 Ceased WO2006087550A2 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof

Country Status (6)

Country Link
EP (1) EP1853626A2 (en)
JP (1) JP2008530194A (en)
AU (1) AU2006215406A1 (en)
CA (1) CA2598080A1 (en)
GB (1) GB0503434D0 (en)
WO (1) WO2006087550A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566020A (en) 2005-09-09 2012-08-31 Novartis Ag Prion-specific peptoid reagents
JP4777225B2 (en) * 2006-12-04 2011-09-21 キヤノン株式会社 Discharge liquid and discharge method
DK2220030T3 (en) * 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
JP5554528B2 (en) * 2009-09-08 2014-07-23 国立大学法人 岡山大学 Novel amyloid β aggregate-binding peptide and method for testing amyloid disease using the novel amyloid β aggregate-binding peptide
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2013082045A1 (en) * 2011-11-28 2013-06-06 Buck Institute For Age Research Netrin loop peptide mimetics and uses thereof
WO2014184596A2 (en) * 2013-05-17 2014-11-20 Szegedi Tudomanyegyetem SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY
JP6660877B2 (en) * 2013-09-26 2020-03-11 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amyloid-β-binding peptide and its use for the treatment and diagnosis of Alzheimer's dementia
ES3040431T3 (en) * 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN106800590B (en) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 Polypeptide combining multiple amyloid protein monomers and aggregates and application thereof
US11970521B2 (en) * 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
KR101956302B1 (en) * 2016-11-30 2019-03-11 연세대학교 산학협력단 intracellular pH-responsive fusion peptide, phamaceutical composition for treatment of protein aggregation and misfolding related diseases
AR115758A1 (en) * 2018-07-13 2021-02-24 Cj Cheildang Corp COMPOSITION INCLUDING THE LACTOBACILLUS PLANTARUM STRAIN CJLP475 AND THE LACTOBACILLUS PLANTARUM STRAIN CJLP243 AND USE OF THE SAME
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU781292B2 (en) * 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2006087550A3 (en) 2007-05-24
CA2598080A1 (en) 2006-08-24
GB0503434D0 (en) 2005-03-30
AU2006215406A1 (en) 2006-08-24
WO2006087550A2 (en) 2006-08-24
JP2008530194A (en) 2008-08-07
EP1853626A2 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
WO2007070659A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008081701A1 (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2011036443A3 (en) Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
MXPA04008077A (en) ANTI-Abeta ANTIBODIES AND THEIR USE.
WO2006069246A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ATE506957T1 (en) PROPHYLACTIC/THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
JP2006506942A5 (en)
WO2005058959A3 (en) Treatment of viral infections
NO331277B1 (en) Pharmaceutical composition comprising polypeptide / nucleic acid for the treatment of retinal degenerative diseases, vector, isolated polypeptide, purified antibody and use of polypeptide, nucleic acid and antibody, and methods and kits
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2008087224A3 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2006032697A3 (en) MODIFIED VPl-CAPSID PROTEIN OF PARVOVIRUS B19
JP2019038772A5 (en)
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2006075253A3 (en) Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
WO2008070586A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
EP1666880A4 (en) SCREENING METHOD
WO2007049065A3 (en) Vwfa, collagen and kunitz domain containing protein
WO2006018431A3 (en) Peptides for the treatment of herpes virus infections
ATE397753T1 (en) SCREENING METHOD FOR A PROPHYLACTIC AND THERAPEUTIC SUBSTANCE FOR KIDNEY DISEASE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006215406

Country of ref document: AU

Ref document number: 2598080

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007555695

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006709776

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2006215406

Country of ref document: AU

Date of ref document: 20060216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006215406

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 561659

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2006709776

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006709776

Country of ref document: EP